This clinical trial is focused on studying a type of lung cancer known as metastatic non-squamous non-small cell lung cancer (NSCLC). This is a form of lung cancer that has spread to other parts of the body and does not involve squamous cells, which are flat cells found in the lining of the airways. The study will test a new treatment called Visugromab (CTL-002), which is a special type of protein designed to help the immune system fight cancer. This treatment will be given in combination with other medications: Pembrolizumab, Pemetrexed, and Carboplatin. These medications are part of a group of treatments known as immunochemotherapy, which combines immune system-based treatments with chemotherapy to target cancer cells more effectively.

The purpose of the study is to investigate how well Visugromab works when used with these other treatments compared to a placebo, which is a substance with no active medication. Participants in the study will receive either Visugromab or a placebo, along with Pembrolizumab, Pemetrexed, and Carboplatin. The study will be conducted over a period of time, with regular check-ups and assessments to monitor the effects of the treatment on the cancer and any side effects that may occur. The goal is to see if the combination of these treatments can improve the response to cancer and help manage the disease more effectively.

Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to gather information on how the treatment affects their cancer. The study aims to provide valuable insights into the potential benefits of using Visugromab in combination with other treatments for people with metastatic non-squamous non-small cell lung cancer. This research could lead to new and improved treatment options for patients with this type of lung cancer in the future.